• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Alltrna Announces Updates to Its Board of Directors

    7/17/24 8:00:00 AM ET
    $APRE
    $CYTK
    $EVLO
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APRE alert in real time by email
    • Chris Schade appointed as Board Chairperson
    • Lynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of Directors

    CAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Operating Officer of Ionis Pharmaceuticals, Robert Plenge, M.D., Ph.D., Executive Vice President, Chief Research Officer and Head of Research at Bristol Myers Squibb, and Nancy Simonian, M.D., Founding CEO of Syros Pharmaceuticals. They join Board Directors Michelle Werner, Alltrna CEO and Flagship Pioneering CEO-Partner, and Lovisa Afzelius, Ph.D., MBA, Alltrna Co-Founder and Flagship Pioneering General Partner.

    www.alltrna.com. (PRNewsfoto/Alltrna)" alt="Alltrna unlocks tRNA biology to correct disease. The company's platform incorporates AI/ML tools to learn the tRNA language and deliver diverse programmable molecules with broad therapeutic potential. Alltrna has an unprecedented opportunity to advance a single tRNA medicine to unify treatment across a wide range of diseases with the same underlying genetic mutation. Alltrna was founded in 2018 by Flagship Pioneering. For more info, visit www.alltrna.com. (PRNewsfoto/Alltrna)">

    "As a Co-Founder of Alltrna and Board Chairperson since 2018, I've been honored to guide Alltrna from ideation to platform creation to in vivo preclinical proof-of-concept," said Noubar Afeyan, Ph.D., Founder and CEO of Flagship Pioneering and Co-Founder of Alltrna. "As Alltrna looks to bring its first tRNA medicines into the clinic, Chris' expertise in company development, partnering, and financing will be indispensable. With Chris leading the Board and the additions of Lynne, Robert, and Nancy, Alltrna is exceptionally well-positioned to fulfill this enormous opportunity leveraging the unique biology of tRNA to scale the development of genetic medicines for many diseases."

    "Noubar's extraordinary vision as Board Chairperson during Alltrna's critical formative years have brought us to our leadership position in the genetic medicines community today, and Chris's diverse experience and insights in helping grow biotech companies will be invaluable as we build on this momentum to pioneer tRNA medicine and further build Alltrna and its platform to support innovation and scale," added Michelle C. Werner, CEO of Alltrna and CEO-Partner of Flagship Pioneering. "I also look forward to working closely with Lynne, Robert, and Nancy and leveraging their extensive experience to advance our first universal medicine for Stop Codon Disease to the clinic."

    "I am honored to be Chairperson and look forward to continuing to work with Michelle and Lovisa at this pivotal time as Alltrna charts its path to clinical trials and beyond," said Chris Schade, Board Chairperson, Alltrna and Growth Partner, Flagship Pioneering. "With proof-of-concept in vivo data showing its platform can be leveraged to engineer and modify tRNAs for universal readthrough of a shared genetic mutation found in thousands of rare diseases, Alltrna is leading the field in turning tRNA's sophisticated biology into scalable genetic medicines. I am also thrilled to welcome Lynne, Robert, and Nancy to Alltrna's Board of Directors. Their diverse expertise spanning all aspects of drug development, from translational research to operations and strategy, will serve Alltrna well as the company advances this completely new class of RNA medicines."

    Christian S. Schade

    Mr. Schade has more than 30 years of private and public pharmaceutical and biotechnology industry experience, as well as broad corporate finance expertise from his tenure in investment banking. Prior to Flagship, he served as the Chairman and CEO of Aprea Therapeutics Inc. (NASDAQ:APRE), a clinical-stage biopharmaceutical company. Prior to Aprea, Schade's previous roles include CEO of Novira (acquired by Johnson & Johnson), Executive Vice President (EVP) and Chief Financial Officer (CFO) of Omthera Pharmaceuticals, Inc. (NASDAQ:OMTH, acquired by AstraZeneca Plc))), EVP and CFO at NRG Energy Inc. (NYSE:NRG), and Senior Vice President of Administration and CFO at Medarex, Inc. (NASDAQ:MEDX, acquired by Bristol Myers Squibb))). Before Medarex, Schade served as Managing Director at Merrill Lynch in London and held various corporate finance and capital markets positions in New York and London for both Merrill Lynch and JP Morgan Chase & Co. Schade currently serves as Chair of the Board of Directors of Omega Therapeutics, Inc. (NASDAQ:OMGA), and serves on the Boards of Ring Therapeutics, Valo Health, and Integra LifeSciences Inc. (NASDAQ:IART), where he chairs the Audit and Finance Committees.

    Lynne Parshall

    Ms. Parshall is a seasoned biotechnology leader with more than 35 years in industry. An attorney by training, she spent more than 30 years as the founding Chief Operating Officer of Ionis Pharmaceuticals and subsequently as a Strategic Advisor to the CEO, overseeing legal, finance, business development, portfolio management, strategic planning, manufacturing, regulatory, alliance management, and other functions. While at Ionis she was responsible for raising more than $6 billion in financing from equity-based securities and corporate partner transactions. Ms. Parshall has sat on numerous public and private company Boards of Directors and has extensive Audit Committee and corporate governance experience. She currently is on the Boards of Ionis Pharmaceuticals (NASDAQ:IONS), Cytokinetics (NASDAQ:CYTK), Foghorn Therapeutics (NASDAQ:FHTX), Ring Therapeutics, Repertoire Immune Medicines, and Celdara Medical. She was previously Chair of the Board of Akcea Therapeutics prior to its acquisition. Prior to working in industry, she was a partner at the Cooley law firm with a practice focusing on securities law and biotechnology corporate partnering.

    Robert Plenge, M.D., Ph.D.

    Dr. Plenge is Executive Vice President, Chief Research Officer and Head of Research at Bristol Myers Squibb (BMS). He leads scientific activities across eleven research sites around the world all focused on transforming patients' lives through science. Prior to his current role, Dr. Plenge served as head of Discovery & Translational Sciences at BMS, which spanned all therapeutic areas at the company. He joined BMS as part of the acquisition of Celgene in November 2019. At Celgene, he served as Vice President, Immunology & Inflammation portfolio, Research & Early Development. Prior to joining Celgene, Dr. Plenge was Vice President and Head of Translational Medicine at Merck. Prior to his roles in industry, he was an Assistant Professor of Medicine at Harvard Medical School and an Associate Member of the Broad Institute while practicing clinical rheumatology and running a research laboratory at Brigham & Women's Hospital. Dr. Plenge is an author of more than 125 manuscripts published in peer-reviewed journals and a recipient of several academic and corporate awards. He currently serves on the Board of Directors for the PhRMA Foundation.

    Nancy Simonian, M.D.

    Dr. Simonian is a physician-scientist who has dedicated her career to developing drugs for people with serious diseases. She is the Founding CEO and a member of the Board of Directors of Syros Pharmaceuticals, a biopharmaceutical company committed to advancing novel approaches to treating cancer based on altering gene expression. Prior to Syros, she was Chief Medical Officer at Millennium Pharmaceuticals and Vice President of Clinical Development at Biogen. At Millennium, Dr. Simonian oversaw the successful development of VELCADE® to treat multiple myeloma, and mantle cell lymphoma, NINLARO® to treat multiple myeloma and ENTYVIO® to treat inflammatory bowel disease. At Biogen, she played a central role in developing AVONEX® and TYSABRI® for multiple sclerosis. Dr. Simonian started her career as an assistant professor at Harvard Medical School and Massachusetts General Hospital. She currently serves as a Director of Syros (NASDAQ:SYRS) and the Damon Runyon Cancer Research Foundation. She previously served as a Director of Seagen (NASDAQ:SGEN, acquired by Pfizer in 2023))), Evelo (NASDAQ:EVLO), and ArQule (NASDAQ:ARQL, acquired by Merck in 2020))).

    About Stop Codon Disease

    Stop Codon Disease encompasses thousands of rare and common diseases that stem from premature termination codons (PTC) also called nonsense mutations, where the code for an amino acid has been mutated into a premature "stop" codon. This results in a truncated or shortened protein product with no or altered biological activity that causes disease. Approximately 10% of all people with a genetic disease have Stop Codon Disease, representing approximately 30 million people worldwide. Alltrna is engineering tRNA medicines that can read these PTC mutations and deliver the desired amino acid, thereby restoring the production of the full-length protein.

    About Alltrna

    Alltrna unlocks tRNA biology to treat disease. The company's platform incorporates AI/ML tools to develop and deliver diverse programmable molecules with broad therapeutic potential. Alltrna has an unprecedented opportunity to advance a single tRNA medicine to readthrough premature stop codons and unify treatment across a wide range of diseases with the same underlying genetic mutations. Alltrna was founded in 2018 by Flagship Pioneering. For more info, visit www.alltrna.com.

    About Flagship Pioneering

    Flagship Pioneering invents and builds bioplatform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than $75 billion in aggregate value. To date, Flagship has deployed over $3.8 billion in capital toward the founding and growth of its pioneering companies alongside more than $27 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 40 companies, including Foghorn Therapeutics (NASDAQ:FHTX), Moderna (NASDAQ:MRNA), Sana Biotechnology (NASDAQ:SANA), Generate Biomedicines, Inari, Indigo Agriculture, and Tessera Therapeutics.

    Media Contacts

    Jessica Yingling, Ph.D., Little Dog Communications Inc., [email protected], +1.858.344.8091

    Josephine Zorbo, Ph.D., Flagship Pioneering, [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/alltrna-announces-updates-to-its-board-of-directors-302198766.html

    SOURCE Alltrna

    Get the next $APRE alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $APRE
    $CYTK
    $EVLO
    $FHTX

    CompanyDatePrice TargetRatingAnalyst
    Sana Biotechnology Inc.
    $SANA
    7/3/2025$12.00Overweight
    Morgan Stanley
    Ionis Pharmaceuticals Inc.
    $IONS
    7/1/2025$57.00Equal Weight → Overweight
    Barclays
    NRG Energy Inc.
    $NRG
    6/26/2025$197.00Overweight
    Barclays
    NRG Energy Inc.
    $NRG
    6/13/2025$195.00Strong Buy
    Raymond James
    Cytokinetics Incorporated
    $CYTK
    4/24/2025$55.00Overweight
    Barclays
    Foghorn Therapeutics Inc.
    $FHTX
    4/23/2025$9.00Mkt Outperform
    Citizens JMP
    Ionis Pharmaceuticals Inc.
    $IONS
    4/7/2025$45.00Buy
    H.C. Wainwright
    NRG Energy Inc.
    $NRG
    4/4/2025$129.00Buy
    Goldman
    More analyst ratings

    $APRE
    $CYTK
    $EVLO
    $FHTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley resumed coverage on Sana Biotechnology with a new price target

      Morgan Stanley resumed coverage of Sana Biotechnology with a rating of Overweight and set a new price target of $12.00

      7/3/25 7:51:55 AM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ionis Pharma upgraded by Barclays with a new price target

      Barclays upgraded Ionis Pharma from Equal Weight to Overweight and set a new price target of $57.00

      7/1/25 8:12:05 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Barclays initiated coverage on NRG Energy with a new price target

      Barclays initiated coverage of NRG Energy with a rating of Overweight and set a new price target of $197.00

      6/26/25 8:10:55 AM ET
      $NRG
      Electric Utilities: Central
      Utilities

    $APRE
    $CYTK
    $EVLO
    $FHTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • November 30, 2020 - Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate

      For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm

      11/30/20 5:12:14 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $APRE
    $CYTK
    $EVLO
    $FHTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hayden Michael R bought $477,900 worth of shares (15,000 units at $31.86), increasing direct ownership by 43% to 50,219 units (SEC Form 4)

      4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

      5/2/25 4:38:26 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President/CEO Gilad Oren bought $10,110 worth of shares (5,500 units at $1.84), increasing direct ownership by 2% to 345,620 units (SEC Form 4)

      4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

      4/4/25 7:30:11 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Bancel Stephane bought $5,004,318 worth of shares (160,314 units at $31.22) (SEC Form 4)

      4 - Moderna, Inc. (0001682852) (Issuer)

      3/4/25 4:27:16 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $APRE
    $CYTK
    $EVLO
    $FHTX
    SEC Filings

    See more
    • Foghorn Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Foghorn Therapeutics Inc. (0001822462) (Filer)

      7/1/25 4:40:46 PM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sana Biotechnology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Sana Biotechnology, Inc. (0001770121) (Filer)

      6/23/25 10:10:46 AM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Foghorn Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Foghorn Therapeutics Inc. (0001822462) (Filer)

      6/17/25 4:01:55 PM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APRE
    $CYTK
    $EVLO
    $FHTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Integra LifeSciences Announces First Patient Enrolled in Acclarent AERA® Pediatric Registry

      PRINCETON, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Corporation (NASDAQ:IART), a leading global medical technology company, is proud to announce enrollment of the first patient in the Acclarent AERA Pediatric Registry, a prospective, multi-center observational registry evaluating the real-world use of the AERA Eustachian Tube Balloon Dilation System in children. This inaugural enrollment marks the focused effort to measure the ongoing, real-world clinical performance of AERA in pediatric patients with obstructive Eustachian tube dysfunction (ETD). Dr. Prasad Thottam at Michigan Pediatric ENT Associates enrolled the first patient; "We are proud to support this i

      7/2/25 4:09:00 PM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Flagship Pioneering Unveils Terrana Biosciences to Deliver Adaptive, Targeted Agricultural Solutions through a Novel RNA Technology Platform

      Solutions focus on enhancing crop resilience, protecting yields, and addressing critical challenges in the global food system The company emerges after four years of platform development with an initial commitment of $50 million from Flagship Pioneering CAMBRIDGE, Mass., July 1, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Terrana Biosciences™, a company pioneering RNA-based agricultural solutions to deliver protective and enhanced crop traits without altering the plant genome. Through its proprietary RNA technology platform, Terrana is developing targeted products designed to work at any time in a plant's lifecycle, enabling a continuous prod

      7/1/25 6:30:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA

      New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg SPINRAZA® (nusinersen) Final results from the landmark NURTURE study highlight the profound impact of early treatment with 12 mg SPINRAZA in clinically presymptomatic SMA with 92% of children achieving the ability to walk independently CAMBRIDGE, Mass., June 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy (SMA). These latest findings from

      6/27/25 10:00:23 AM ET
      $BIIB
      $IONS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $APRE
    $CYTK
    $EVLO
    $FHTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP Research & Development Malik Fady Ibraham exercised 2,000 shares at a strike of $10.60 and sold $67,520 worth of shares (2,000 units at $33.76) (SEC Form 4)

      4 - CYTOKINETICS INC (0001061983) (Issuer)

      7/8/25 4:21:58 PM ET
      $CYTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Bishop Hans Edgar was granted 7,842 shares, increasing direct ownership by 0.13% to 5,828,955 units (SEC Form 4)

      4 - Sana Biotechnology, Inc. (0001770121) (Issuer)

      7/8/25 4:17:31 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • EVP & Chief Financial Officer Knight Lea Daniels covered exercise/tax liability with 2,561 shares, decreasing direct ownership by 4% to 58,578 units (SEC Form 4)

      4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

      7/7/25 5:06:50 PM ET
      $IART
      Medical/Dental Instruments
      Health Care

    $APRE
    $CYTK
    $EVLO
    $FHTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ionis Pharmaceuticals Inc.

      SC 13G/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

      11/14/24 8:34:57 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Syros Pharmaceuticals Inc.

      SC 13G/A - Syros Pharmaceuticals, Inc. (0001556263) (Subject)

      11/14/24 5:28:08 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Syros Pharmaceuticals Inc.

      SC 13G/A - Syros Pharmaceuticals, Inc. (0001556263) (Subject)

      11/14/24 5:24:48 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APRE
    $CYTK
    $EVLO
    $FHTX
    Financials

    Live finance-specific insights

    See more
    • Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

      Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show children with SMA previously treated with gene therapy experienced a substantial slowing of neurodegeneration and clinically meaningful improvements in motor function following initiation of salanersenBased on these encouraging Phase 1 data, Biogen is engaging with regulators to advance salanersen to registrational stage studies, building on extensive experience in SMA CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced topline results from the Phase 1 study of

      6/25/25 7:30:37 AM ET
      $BIIB
      $IONS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • NRG Energy, Inc. Reports First Quarter 2025 Results and Reaffirms 2025 Financial Guidance

      Reporting $750 million of GAAP Net Income, $531 million of Adjusted Net Income, and $2.68 Adjusted EPS Announcing the strategic acquisition of a premier portfolio of 13 GW of natural gas generation primarily in PJM and ERCOT and 6 GW C&I VPP platform from LS Power for cash and stock Closed acquisition of 738 MW of flexible natural gas generation in Texas at an attractive value well below new build cost 1.5 GW of eligible Texas Energy Fund projects are now all in active due diligence review, with the recent addition of Greens Bayou Reaffirming 2025 guidance ranges and capital allocation NRG Energy, Inc. (NYSE:NRG) today reports GAAP Net Income of $750 million for the three mon

      5/12/25 7:21:00 AM ET
      $NRG
      Electric Utilities: Central
      Utilities
    • NRG Energy Inc. to Acquire Premier Power Portfolio from LS Power; Transforming Generation Fleet for Growing Demand

      Doubles NRG's Generation Capacity with Irreplicable Natural Gas Assets in the Northeast and Texas; Adds Leading C&I VPP Platform Immediately and Highly Accretive to Adjusted EPS; NRG Increases 5-year Adjusted EPS CAGR from +10% to +14%, Before Upside Opportunities Enhances Capabilities to Serve Rapidly Growing Demand with Tailored, Customized Supply Solutions for Customers Enhances Credit Profile and Supports $1 Billion in Annual Share Repurchases Until < 3.0x Leverage Target Reached; then Returning to 80/20 Capital Allocation Framework NRG to Host Conference Call and Webcast Today at 9:00 a.m. Eastern Time NRG Energy Inc. (NYSE:NRG) and LS Power Equity Advisors, LLC ("LS Power") today

      5/12/25 7:00:00 AM ET
      $NRG
      Electric Utilities: Central
      Utilities

    $APRE
    $CYTK
    $EVLO
    $FHTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Ted Myles Joins Cellarity as Chief Executive Officer

      Myles, a Biopharma Industry Veteran, Will Also Join Flagship Pioneering as a CEO-Partner CAMBRIDGE, Mass., May 12, 2025 /PRNewswire/ -- Cellarity, a life sciences company transforming the way medicines are created, and Flagship Pioneering, the bioplatform innovation company, today announced the appointment of Ted Myles as Chief Executive Officer of Cellarity and CEO-Partner at Flagship. Myles is a seasoned biopharma leader with deep experience and a track record for building clinical and commercial-stage companies. Previously, he was Chief Financial Officer and Chief Operating

      5/12/25 8:00:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors

      CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the election of Neil Gallagher, M.D., Ph.D., and Stuart Duty, to its Board of Directors. "Neil and Stuart are experienced leaders with decades of deep and multifaceted understanding of the biotechnology industry," said Adrian Gottschalk, President and Chief Executive Officer of Foghorn. "We are pleased to welcome them to our Board of Directors and will leverage their strategic insights as we further advance our pipeline." Dr. Gallagher

      5/1/25 7:00:00 AM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Flagship Pioneering Appoints Rahul Kakkar as CEO-Partner and CEO of Quotient Therapeutics

      CAMBRIDGE, Mass., April 29, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Quotient Therapeutics, a company pioneering somatic genomics, today announced that Rahul Kakkar, M.D., will join Flagship Pioneering as CEO-Partner and Quotient Therapeutics as Chief Executive Officer. Dr. Kakkar is a biotech entrepreneur and physician-scientist with nearly 20 years of professional experience founding and building biotechnology companies and practicing medicine. Previously, he served as President and CEO of Tome Biosciences, a genome engineering biotec

      4/29/25 8:00:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)